We are live on ! Find out more
MLTX icon

MoonLake Immunotherapeutics
MLTX

114 hedge funds and large institutions have $2.99B invested in MoonLake Immunotherapeutics in 2024 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 44 increasing their positions, 37 reducing their positions, and 33 closing their positions.

New
Increased
Maintained
Reduced
Closed

19% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 37

0.21% more ownership

Funds ownership: 99.09% → 99.3% (+0.21%)

9% less funds holding

Funds holding: 125 → 114 (-11)

15% less call options, than puts

Call options by funds: $22.9M | Put options by funds: $26.9M

15% less capital invested

Capital invested by funds: $3.53B → $2.99B (-$543M)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

33% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 33

Holders
114
Holders Change
-11
Holders Change %
-8.8%
% of All Funds
1.64%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
22
Increased
44
Reduced
37
Closed
33
Calls
$22.9M
Puts
$26.9M
Net Calls
-$4.03M
Net Calls Change
+$3.54M

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$41.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$28.4M
3
Marshall Wace
Marshall Wace
United Kingdom
+$27.7M
4
Holocene Advisors
Holocene Advisors
New York
+$26.8M
5
Citadel Advisors
Citadel Advisors
Florida
+$16.3M

Top Sellers

Rank Fund Capital Flow
1
DGM
Darwin Global Management
Jersey
-$62.8M
2
FC
Finepoint Capital
Massachusetts
-$29M
3
TCM
TimesSquare Capital Management
New York
-$15.2M
4
Invesco
Invesco
Georgia
-$14.4M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$9.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
TLP
126
Tri Locum Partners
New York
– -$2.87M -47,604 Closed
Simplex Trading
127
Simplex Trading
Illinois
– -$1.91M -35,179 Closed
ECM
128
ExodusPoint Capital Management
New York
– -$1.72M -28,417 Closed
WMSA
129
Weiss Multi-Strategy Advisers
New York
– -$1.29M -21,336 Closed
N
130
Natixis
France
– -$1.27M -20,317 Closed
SGCM
131
Sand Grove Capital Management
United Kingdom
– -$1.21M -20,000 Closed
Squarepoint
132
Squarepoint
New York
– -$1.14M -18,903 Closed
LIP
133
Lighthouse Investment Partners
Florida
– -$1.13M -18,728 Closed
Mirae Asset Global Investments
134
Mirae Asset Global Investments
South Korea
– -$1.13M -18,699 Closed
Hudson Bay Capital Management
135
Hudson Bay Capital Management
Connecticut
– -$906K -15,000 Closed
FC
136
FORA Capital
Florida
– -$871K -14,425 Closed
YIH
137
Y-Intercept (HK)
Hong Kong
– -$678K -11,227 Closed
EAM
138
Exome Asset Management
New York
– -$588K -9,744 Closed
FRM
139
Fox Run Management
Connecticut
– -$326K -5,398 Closed
WS
140
Wedbush Securities
California
– -$269K -4,455 Closed
Two Sigma Investments
141
Two Sigma Investments
New York
– -$233K -3,853 Closed
CC
142
Corton Capital
Ontario, Canada
– -$212K -3,505 Closed
FCM
143
Farallon Capital Management
California
– -$205K -3,400 Closed
SWP
144
Stratos Wealth Partners
Ohio
– -$202K -3,350 Closed
Citigroup
145
Citigroup
New York
– -$139K -2,297 Closed
Allspring Global Investments
146
Allspring Global Investments
North Carolina
– -$5.8K -96 Closed
HT
147
Headlands Technologies
Illinois
– -$5.43K -90 Closed
2 3 4 5
6

MLTX Hedge Fund Activity: Q1 2024 in Review

114 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q1 2024, worth a combined $2.99B — down 15% from $3.53B a quarter earlier.

Sellers outnumbered buyers: 33 funds closed out of MLTX and 22 opened new positions — a net loss of 11 holders — while 37 trimmed existing stakes and 44 added.

The largest buyer was Adage Capital Partners, adding an estimated $41.2M. The largest seller was Darwin Global Management, exiting entirely with an estimated $62.8M sold.

  • 114 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q1 2024, down from 125 in Q4 2023.
  • Funds reported $2.99B of MoonLake Immunotherapeutics stock for Q1 2024, down 15% quarter-over-quarter.
  • 22 funds opened new MoonLake Immunotherapeutics positions in Q1 2024 and 33 closed out, a net change of -11 holders.
  • The largest MoonLake Immunotherapeutics buyer in Q1 2024 was Adage Capital Partners, an estimated $41.2M added.
  • The largest MoonLake Immunotherapeutics seller in Q1 2024 was Darwin Global Management, an estimated $62.8M sold.

Based on aggregated 13F filings for Q1 2024.